Thank you!
One of the best Endometriosis Videos I have ever seen. You did a great job and our best wishes to you.https://www.youtube.com/watch?v=bVZ8nXVtlvU
Showing posts with label pcbs. Show all posts
Showing posts with label pcbs. Show all posts
Saturday, March 15, 2014
Sunday, April 24, 2011
Eggsploitation
04-06-11: Award-winning documentary, 'Eggsploitation', was shown at Boston College Law School. Risks of lupron, and the lack of data-tracking of women who undergo egg donation and IVF, were discussed. 'RESOLVE' (the organization that alleges to "educate, advocate, and support the infertile") had in attendance a Board Member who attempted to discredit 'Eggsploitation' as "biased" and 'not representative of the industry'. 'RESOLVE's' Board Member failed to inform the audience of 'RESOLVE's' conflicts of interest: RESOLVE has a history of receiving hundreds of thousands of dollars from the fertility drug manufacturers, fertility clinics, and fertility doctors.
From: http://www.lupronvictimshub.com/
From: http://www.lupronvictimshub.com/
Global Endometriosis Market to Reach $1.3 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.
Monday, April 4, 2011
San Jose, CA (Vocus/PRWEB) April 04, 2011
Endometriosis is the most common health problem among women. As per the estimates of World Endometriosis Research Foundation, an estimated 170 million women suffer from endometriosis globally. Endometriosis-related healthcare costs and productivity losses exceed US$4,000 per patient annually. Annual direct and indirect endometriosis-related costs are estimated to cross US$20 to US$25 billion in the US over the coming years. The disease affects reproductive age women more compared to post-menopausal women. Endometriosis affects more than 90 million women of reproductive age globally. The disease represents one of the major causes of female infertility and constitutes for about 30% of infertility cases in women. More than 7.8 million women in the US suffer from endometriosis-related symptoms, which include chronic pelvic pain, dysmenorrhea, and infertility.
Gonadotropin-Releasing Hormone GnRH agonists, Progestins, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and contraceptives are the major therapeutic options available for the treatment of endometriosis. The present drugs are characterized by safety and efficacy concerns. Huge unmet medical need exists for novel medication with improved safety profile and minimal side effects. Lupron Depot from Abbott Laboratories, Depo-Provera and Synarel from Pfizer, are the major drugs approved for the treatment of endometriosis. Abbott's Lupron (Leuprolide) represents one of the leading drugs for the treatment of endometriosis.
The global endometriosis market is led by the US, as stated by a new market research report on Endometriosis. Europe represents the next largest region, while growth is expected to emanate mainly from the 'Rest of the world' market, which is expected to depict a compounded annualized growth of more than 6.0% during 2009-2017. The future looks promising for endometriosis, with increasing efforts being made in research, and novel treatment emerging in the field of surgical as well as pharmaceutical treatment. In addition, myths are being dispelled regarding the disease, and alternative methods are being readily accepted. Non-invasive diagnostics, including next-generation MRIs, are forecast to become major tools for the diagnosis of endometriosis, although laparoscopy, an invasive surgery, still remains the gold standard for performing disease diagnosis. Genetic and biomolecular diagnostic tests are also being trailed.
Drugs that are expected to drive future market growth include Abarelix, SERMs (Selective Estrogen Receptor Modulators), Extracellular Matrix Modulators, Terbutaline, and RU-486. Abarelix, for instance, is a GnRH antagonist, presently undergoing clinical trials in the US for its use in endometriosis. The emergence of certain other promising innovative drugs, including Repros Therapeutics' Proellex, Neurocrine's Elagolix, and Bayer HealthCare Pharmaceuticals' Visanne (Dienogest) is forecast to have a robust impact on the endometriosis market in future. Elagolix is the first oral non-peptide gonadotropin-releasing hormone (GnRH) antagonist. Meanwhile, Proellex acts by selectively blocking the activity of progesterone, and allows the secretions of tonic hormone by alleviating the negative side effects of GnRHa. Besides pipeline drugs, Angiogenesis therapy is forecast to be one of the key potential treatment options for endometriosis, whether used alone or as an adjunct therapy. Angiogenesis theory holds that endometriosis lesions could be destroyed by cutting off the blood supply.
Major players profiled in the report include Abbott Laboratories, AEterna Zentaris Inc., AstraZeneca Plc., Bayer HealthCare Pharmaceuticals Inc., Eli Lilly and Company, Meditrina Pharmaceuticals Inc., Neurocrine Biosciences Inc., Paladin Labs Inc., Pfizer Inc., Repros Therapeutics Inc., among others.
The research report titled "Endometriosis: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of endometriosis, current market trends, key growth drivers, the available treatment, overview of major drugs, insight into current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for Endometriosis treatment for the years 2009 through 2017 for the following geographic markets - US, Canada, Japan, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit - www.strategyr.com/Endometriosis_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
E-mail: press(at)StrategyR(dot)com
Web Site: www.StrategyR.com/
# # #
For the original version on PRWeb visit: www.prweb.com/releases/prwebendometriosis/laproscopy/prweb8257835.htm
http://sfgate.com/cgi-bin/article.cgi?f=/g/a/2011/04/04/prweb8257835.DTL
San Jose, CA (Vocus/PRWEB) April 04, 2011
Endometriosis is the most common health problem among women. As per the estimates of World Endometriosis Research Foundation, an estimated 170 million women suffer from endometriosis globally. Endometriosis-related healthcare costs and productivity losses exceed US$4,000 per patient annually. Annual direct and indirect endometriosis-related costs are estimated to cross US$20 to US$25 billion in the US over the coming years. The disease affects reproductive age women more compared to post-menopausal women. Endometriosis affects more than 90 million women of reproductive age globally. The disease represents one of the major causes of female infertility and constitutes for about 30% of infertility cases in women. More than 7.8 million women in the US suffer from endometriosis-related symptoms, which include chronic pelvic pain, dysmenorrhea, and infertility.
Gonadotropin-Releasing Hormone GnRH agonists, Progestins, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and contraceptives are the major therapeutic options available for the treatment of endometriosis. The present drugs are characterized by safety and efficacy concerns. Huge unmet medical need exists for novel medication with improved safety profile and minimal side effects. Lupron Depot from Abbott Laboratories, Depo-Provera and Synarel from Pfizer, are the major drugs approved for the treatment of endometriosis. Abbott's Lupron (Leuprolide) represents one of the leading drugs for the treatment of endometriosis.
The global endometriosis market is led by the US, as stated by a new market research report on Endometriosis. Europe represents the next largest region, while growth is expected to emanate mainly from the 'Rest of the world' market, which is expected to depict a compounded annualized growth of more than 6.0% during 2009-2017. The future looks promising for endometriosis, with increasing efforts being made in research, and novel treatment emerging in the field of surgical as well as pharmaceutical treatment. In addition, myths are being dispelled regarding the disease, and alternative methods are being readily accepted. Non-invasive diagnostics, including next-generation MRIs, are forecast to become major tools for the diagnosis of endometriosis, although laparoscopy, an invasive surgery, still remains the gold standard for performing disease diagnosis. Genetic and biomolecular diagnostic tests are also being trailed.
Drugs that are expected to drive future market growth include Abarelix, SERMs (Selective Estrogen Receptor Modulators), Extracellular Matrix Modulators, Terbutaline, and RU-486. Abarelix, for instance, is a GnRH antagonist, presently undergoing clinical trials in the US for its use in endometriosis. The emergence of certain other promising innovative drugs, including Repros Therapeutics' Proellex, Neurocrine's Elagolix, and Bayer HealthCare Pharmaceuticals' Visanne (Dienogest) is forecast to have a robust impact on the endometriosis market in future. Elagolix is the first oral non-peptide gonadotropin-releasing hormone (GnRH) antagonist. Meanwhile, Proellex acts by selectively blocking the activity of progesterone, and allows the secretions of tonic hormone by alleviating the negative side effects of GnRHa. Besides pipeline drugs, Angiogenesis therapy is forecast to be one of the key potential treatment options for endometriosis, whether used alone or as an adjunct therapy. Angiogenesis theory holds that endometriosis lesions could be destroyed by cutting off the blood supply.
Major players profiled in the report include Abbott Laboratories, AEterna Zentaris Inc., AstraZeneca Plc., Bayer HealthCare Pharmaceuticals Inc., Eli Lilly and Company, Meditrina Pharmaceuticals Inc., Neurocrine Biosciences Inc., Paladin Labs Inc., Pfizer Inc., Repros Therapeutics Inc., among others.
The research report titled "Endometriosis: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of endometriosis, current market trends, key growth drivers, the available treatment, overview of major drugs, insight into current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for Endometriosis treatment for the years 2009 through 2017 for the following geographic markets - US, Canada, Japan, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit - www.strategyr.com/Endometriosis_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
E-mail: press(at)StrategyR(dot)com
Web Site: www.StrategyR.com/
# # #
For the original version on PRWeb visit: www.prweb.com/releases/prwebendometriosis/laproscopy/prweb8257835.htm
http://sfgate.com/cgi-bin/article.cgi?f=/g/a/2011/04/04/prweb8257835.DTL
Sunday, March 27, 2011
Tuesday, March 15, 2011
Tuesday, February 15, 2011
Endometriosis: Natural History, Diagnosis, and Outcomes (ENDO STUDY)
Well not much being done government-wise.
Heres the latest from the Nih.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Principal investigator: Germaine M. Buck Louis, Ph.D., M.S.
Along with a multidisciplinary group of colleagues from the University of Buffalo, Dr. Buck Louis implemented the Buffalo Women's Gynecologic Health Study. The purpose of this study was to demonstrate that women undergoing laparoscopy could be recruited to participate in an epidemiologic study of endometriosis. A second objective was to determine the feasibility of collecting biospecimens, including omentum fat. One paper from this study has already been published, two others are currently under review.
DESPR Collaborators
· Enrique F. Schisterman, Ph.D.
· Mary L. Hediger, Ph.D.
Selected Publications
Hediger ML, Hartnett HJ, & Buck Louis GM. (2005). Association of endometriosis with body size and figure. Fertility Sterility, 84(5):1366-1374. [Abstract]
Schisterman EF, Whitcomb BW, Louis GMB, & Louis TA. (2005). Lipid adjustment in the analysis of environmental contaminants and human health risks. Environmental Health Perspectives, 113(7):853-857. [Abstract]
Louis GM, Weiner JM, Whitcomb BW, Sperrazza R, Schisterman EF, Lobdell DT, Crickard K, Greizerstein H, & Kostyniak PJ. (2005) Environmental PCB exposure and risk of endometriosis. Human Reproduction, 20(1):279-285. [Abstract]
Whitcomb BW, Schisterman EF, Buck GM, Weiner JM, Greizerstein H, & Kostyniak PJ. (2005). Relative concentrations of organochlorine pesticides and polychlorinated biphenyls in adipose tissue and serum of women of reproductive age. Environmental Toxicology and Pharmacology, 19:203-213.
http://www.nichd.nih.gov/about/org/despr/studies/fecunfert/PCBendo.cfm
Last Update: 06/21/2010
Heres the latest from the Nih.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Principal investigator: Germaine M. Buck Louis, Ph.D., M.S.
Along with a multidisciplinary group of colleagues from the University of Buffalo, Dr. Buck Louis implemented the Buffalo Women's Gynecologic Health Study. The purpose of this study was to demonstrate that women undergoing laparoscopy could be recruited to participate in an epidemiologic study of endometriosis. A second objective was to determine the feasibility of collecting biospecimens, including omentum fat. One paper from this study has already been published, two others are currently under review.
DESPR Collaborators
· Enrique F. Schisterman, Ph.D.
· Mary L. Hediger, Ph.D.
Selected Publications
Hediger ML, Hartnett HJ, & Buck Louis GM. (2005). Association of endometriosis with body size and figure. Fertility Sterility, 84(5):1366-1374. [Abstract]
Schisterman EF, Whitcomb BW, Louis GMB, & Louis TA. (2005). Lipid adjustment in the analysis of environmental contaminants and human health risks. Environmental Health Perspectives, 113(7):853-857. [Abstract]
Louis GM, Weiner JM, Whitcomb BW, Sperrazza R, Schisterman EF, Lobdell DT, Crickard K, Greizerstein H, & Kostyniak PJ. (2005) Environmental PCB exposure and risk of endometriosis. Human Reproduction, 20(1):279-285. [Abstract]
Whitcomb BW, Schisterman EF, Buck GM, Weiner JM, Greizerstein H, & Kostyniak PJ. (2005). Relative concentrations of organochlorine pesticides and polychlorinated biphenyls in adipose tissue and serum of women of reproductive age. Environmental Toxicology and Pharmacology, 19:203-213.
http://www.nichd.nih.gov/about/org/despr/studies/fecunfert/PCBendo.cfm
Last Update: 06/21/2010
Saturday, February 14, 2009
No health insurance? Get help here
From Cnn
Click below for full story
http://www.cnn.com/2009/HEALTH/02/12/ep.health.insurance.help/index.html
Negotiating with doctors and hospitals is just one thing you have to learn how to do when your insurance disappears, says Steve Luptak, executive director of an assistance group called Healthcare Advocacy. "I've had so many people who've just been laid off coming to me for help because they've lost their insurance. They're so stressed, they're so depressed, they feel like it's the end of the world," he says. "But there are things you can do. It's not a futile situation," he says. Watch for more tips for the uninsured »
If you want to try to get new, affordable insurance, or find programs that offer you financial help for doctor's visits, prescription drugs and more, follow these steps:
Step 1: Get good advice
When you get laid off and lose your health insurance, you may need someone in your corner. Several places specialize in helping people find new, affordable insurance and free care:
Healthcare Advocacy
Patient Advocate Foundation
Patient Services Incorporated
Step 2: Search for affordable insurance
With advice from experts at the groups above, begin your search for affordable insurance. Start with COBRA, which means you continue with your employer's insurance, except now you're paying the entire premium on your own. You can learn about COBRA at the Department of Labor's Web site.
If you can't afford to go on COBRA, you're in good company; a recent study by the Commonwealth Fund found that only nine percent of people who are offered COBRA actually use it. Sometimes it's less expensive to buy your own insurance policy rather than going on COBRA. You can compare prices at ehealthinsurance.com.
Step 3: Get your child on SCHIP
Even if you have too much money to qualify for Medicaid, your children may qualify for SCHIP, the State Children's Health Insurance Program. Here's a state-by-state directory of SCHIP programs.
There are other government programs, too. Your entire family may qualify for insurance from a state high-risk pool if you live in a state that has one.
If you think you might quality for Medicaid, see this state-by-state Medicaid directory.
Step 4: Get help with prescription drugs
If you can't afford health insurance -- or if your insurance doesn't include good prescription drug benefits -- look for $4 generic drugs at many major supermarkets and drug stores. Also, your state may offer a discount drug program (after you click, scroll down to see Table 2). You can also check these private groups that offer prescription assistance.
HealthWell Foundation
FamilyWize discount drug card
Needy Meds
Rx Assist
Rx Hope
Chronic Disease Fund
Partnership for Prescription Assistance
The Access Project
Step 5: Find financial assistance for your particular disease
Many diseases have specific foundations that offer financial assistance.
Heart Disease: Heart Support of America
Kidney Disease: American Kidney Fund
HIV/AIDS: The Access Project
Hepatitis: The Access Project
Cancer: see this Empowered Patient for a list of services
Alpha-1 Antitrypsin Deficiency, Chronic Granulomatous Disorder, Huntington's Disease, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension: Caring Voice Coalition
Other rare diseases: National Organization for Rare Diseases
Vision Care: EyeCare America and Vision USA
Step 6: Find free clinics
Federally funded health centers offer free care in both urban and rural areas. Put in your address here and find one near you.
Click below for full story
http://www.cnn.com/2009/HEALTH/02/12/ep.health.insurance.help/index.html
Negotiating with doctors and hospitals is just one thing you have to learn how to do when your insurance disappears, says Steve Luptak, executive director of an assistance group called Healthcare Advocacy. "I've had so many people who've just been laid off coming to me for help because they've lost their insurance. They're so stressed, they're so depressed, they feel like it's the end of the world," he says. "But there are things you can do. It's not a futile situation," he says. Watch for more tips for the uninsured »
If you want to try to get new, affordable insurance, or find programs that offer you financial help for doctor's visits, prescription drugs and more, follow these steps:
Step 1: Get good advice
When you get laid off and lose your health insurance, you may need someone in your corner. Several places specialize in helping people find new, affordable insurance and free care:
Healthcare Advocacy
Patient Advocate Foundation
Patient Services Incorporated
Step 2: Search for affordable insurance
With advice from experts at the groups above, begin your search for affordable insurance. Start with COBRA, which means you continue with your employer's insurance, except now you're paying the entire premium on your own. You can learn about COBRA at the Department of Labor's Web site.
If you can't afford to go on COBRA, you're in good company; a recent study by the Commonwealth Fund found that only nine percent of people who are offered COBRA actually use it. Sometimes it's less expensive to buy your own insurance policy rather than going on COBRA. You can compare prices at ehealthinsurance.com.
Step 3: Get your child on SCHIP
Even if you have too much money to qualify for Medicaid, your children may qualify for SCHIP, the State Children's Health Insurance Program. Here's a state-by-state directory of SCHIP programs.
There are other government programs, too. Your entire family may qualify for insurance from a state high-risk pool if you live in a state that has one.
If you think you might quality for Medicaid, see this state-by-state Medicaid directory.
Step 4: Get help with prescription drugs
If you can't afford health insurance -- or if your insurance doesn't include good prescription drug benefits -- look for $4 generic drugs at many major supermarkets and drug stores. Also, your state may offer a discount drug program (after you click, scroll down to see Table 2). You can also check these private groups that offer prescription assistance.
HealthWell Foundation
FamilyWize discount drug card
Needy Meds
Rx Assist
Rx Hope
Chronic Disease Fund
Partnership for Prescription Assistance
The Access Project
Step 5: Find financial assistance for your particular disease
Many diseases have specific foundations that offer financial assistance.
Heart Disease: Heart Support of America
Kidney Disease: American Kidney Fund
HIV/AIDS: The Access Project
Hepatitis: The Access Project
Cancer: see this Empowered Patient for a list of services
Alpha-1 Antitrypsin Deficiency, Chronic Granulomatous Disorder, Huntington's Disease, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension: Caring Voice Coalition
Other rare diseases: National Organization for Rare Diseases
Vision Care: EyeCare America and Vision USA
Step 6: Find free clinics
Federally funded health centers offer free care in both urban and rural areas. Put in your address here and find one near you.
Wednesday, September 17, 2008
Doctors Try New Approach To Treating Endometriosis
Sep 11, 2008 6:00 pm US/Eastern
BALTIMORE (WJZ) ― A commonly used treatment for breast cancer proves successful at reducing the pain of an entirely different illness.Healthwatch reporter Kellye Lynn says local doctors are combining two drugs to ease the discomfort of endometriosis.Amy Maddox says the severe pain started when her first period arrived 22 years ago. Every month, Amy was on her back. "Intense pain where I couldn't really even function," said Maddox.An official diagnosis didn't come until Amy turned 24. She had endometriosis."I really had to go on the Internet and look it up and see what it really meant," she said."The best way to define endometriosis is to say that it is the menstrual tissue that grows outside the uterus," said Dr. Fermin Barrueto with Mercy Medical Center.It's a disorder that affects up to 10 percent of women--50 percent of premenopausal woman and more than 85 percent of women who have pelvic pain.The strongest pain medications like narcotics may take care of it for two to three hours, but the pain still comes back.Now doctors have found a way to relieve the pain with a pill. They're combining aromatase inhibitors with the endometriosis drug Lupron. "When you use the combination of these two drugs, you have a better chance," Dr. Barrueto said.
READ MORE HERE
Oh man I would ask lots of questions before even considering it.
The Lupron effect can be horrible and sometimes permanant......thats what happened to me anyhow.
Best wishes to all....
BALTIMORE (WJZ) ― A commonly used treatment for breast cancer proves successful at reducing the pain of an entirely different illness.Healthwatch reporter Kellye Lynn says local doctors are combining two drugs to ease the discomfort of endometriosis.Amy Maddox says the severe pain started when her first period arrived 22 years ago. Every month, Amy was on her back. "Intense pain where I couldn't really even function," said Maddox.An official diagnosis didn't come until Amy turned 24. She had endometriosis."I really had to go on the Internet and look it up and see what it really meant," she said."The best way to define endometriosis is to say that it is the menstrual tissue that grows outside the uterus," said Dr. Fermin Barrueto with Mercy Medical Center.It's a disorder that affects up to 10 percent of women--50 percent of premenopausal woman and more than 85 percent of women who have pelvic pain.The strongest pain medications like narcotics may take care of it for two to three hours, but the pain still comes back.Now doctors have found a way to relieve the pain with a pill. They're combining aromatase inhibitors with the endometriosis drug Lupron. "When you use the combination of these two drugs, you have a better chance," Dr. Barrueto said.
READ MORE HERE
Oh man I would ask lots of questions before even considering it.
The Lupron effect can be horrible and sometimes permanant......thats what happened to me anyhow.
Best wishes to all....
Saturday, September 06, 2008
Find Out about ARD, before you have any surgery!
September is Adhesion Related Disorder Awareness Month.
What are Adhesions?
An ADHESION is a type of scar that forms an abnormal connection between two parts of the body. Adhesions can cause severe clinical problems. For example, adhesions involving the female reproductive organs (ovaries, Fallopian tubes) can and do cause infertility, dyspareunia (painful intercourse) and debilitating pelvic pain. Adhesions involving the bowel can cause bowel obstruction or blockage. Adhesions may form elsewhere such as around the heart, spine and in the hand where they lead to other problems.
Adhesions occur in response to injury of various kinds. For example, non-surgical insults such as endometriosis, infection, chemotherapy, radiation and cancer may damage tissue and initiate ADHESIONS. By far the most common kind of ADHESION is the one that forms after surgery. ADHESIONS typically occur at the site of a surgical procedure although they may also occur elsewhere.
An ADHESION is a type of scar that forms an abnormal connection between two parts of the body. Adhesions can cause severe clinical problems. For example, adhesions involving the female reproductive organs (ovaries, Fallopian tubes) can and do cause infertility, dyspareunia (painful intercourse) and debilitating pelvic pain. Adhesions involving the bowel can cause bowel obstruction or blockage. Adhesions may form elsewhere such as around the heart, spine and in the hand where they lead to other problems.
Adhesions occur in response to injury of various kinds. For example, non-surgical insults such as endometriosis, infection, chemotherapy, radiation and cancer may damage tissue and initiate ADHESIONS. By far the most common kind of ADHESION is the one that forms after surgery. ADHESIONS typically occur at the site of a surgical procedure although they may also occur elsewhere.
Dr. David Wiseman - International Adhesions Society
Please visit these site for advocacy news and general education.
International Adhesion Society
International Adhesion Society
Education helps prevent Adhesions!
Endo headlines
Sheesh, what ever happened to altruism.
As I scan the headlines...I feel like a widget to be profitable to corporate shareholders.
Tara's driveDanbury News Times, CT - 2 hours agoThe common wrong conclusion was that Tara had endometriosis, which occurs when endometrial tissue -- tissue normally found only in the lining of the uterus ...
Neurocrine Shares Edge Up After Promising Drug TestsSan Diego Business Journal, CA - 11 hours ago3 following positive mid-stage results for elagolix, a drug candidate aimed at treating endometriosis. Neurocrine shares, traded under the symbol NBIX on ...
Zacks Bull and Bear of the Day Highlights: Allegheny Energy ...PR-Inside.com (Pressemitteilung), Austria - Sep 5, 2008This encouraging data for the treatment of endometriosis should lead to the signing of a major partnership for pivotal trials in 2009. ...AYE - NVTL - HRB
Reunion connects now-healthy children with their medical staffLa Vista Sun, Ne - Sep 5, 2008Because of Colleen's severe endometriosis, the couple, who has lived in Papillion for five years, tried in vitro fertilization, and Colleen finally ...
High Growth Forecasted for the World Endoscopy Systems MarketMarketWatch - Sep 4, 2008... Ovarian Laparoscopy II-32 Endometriosis II-32 Tubal Ligation II-32 Vagina Creation II-33 Laparoscopic Myomectomies II-33 Ovarian Cystectomy II-33 Female ...
Androstenedione Up-Regulation of Endometrial Aromatase Expression ...Journal of Clinical Endocrinology and Metabolism, MD - Sep 4, 2008... in endometrial cells disseminated into the peritoneal cavity may enhance their survival via local estrogen synthesis, which may lead to endometriosis. ...
Extracellularly Signal-Regulated Kinase Activity in the Human ...Journal of Clinical Endocrinology and Metabolism, MD - Sep 4, 2008Context: Endometriosis is an estrogen-dependent disease characterized by the presence of endometrial tissue outside of the uterine cavity, causing pelvic ...
Neurocrine reports positive results from Phase II endometriosis trialTrading Markets (press release), CA - Sep 4, 2008The Petal study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups - elagolix 150mg once daily, elagolix 75mg ...NBIX - OTC:CMTX
As I scan the headlines...I feel like a widget to be profitable to corporate shareholders.
Tara's driveDanbury News Times, CT - 2 hours agoThe common wrong conclusion was that Tara had endometriosis, which occurs when endometrial tissue -- tissue normally found only in the lining of the uterus ...
Neurocrine Shares Edge Up After Promising Drug TestsSan Diego Business Journal, CA - 11 hours ago3 following positive mid-stage results for elagolix, a drug candidate aimed at treating endometriosis. Neurocrine shares, traded under the symbol NBIX on ...
Zacks Bull and Bear of the Day Highlights: Allegheny Energy ...PR-Inside.com (Pressemitteilung), Austria - Sep 5, 2008This encouraging data for the treatment of endometriosis should lead to the signing of a major partnership for pivotal trials in 2009. ...AYE - NVTL - HRB
Reunion connects now-healthy children with their medical staffLa Vista Sun, Ne - Sep 5, 2008Because of Colleen's severe endometriosis, the couple, who has lived in Papillion for five years, tried in vitro fertilization, and Colleen finally ...
High Growth Forecasted for the World Endoscopy Systems MarketMarketWatch - Sep 4, 2008... Ovarian Laparoscopy II-32 Endometriosis II-32 Tubal Ligation II-32 Vagina Creation II-33 Laparoscopic Myomectomies II-33 Ovarian Cystectomy II-33 Female ...
Androstenedione Up-Regulation of Endometrial Aromatase Expression ...Journal of Clinical Endocrinology and Metabolism, MD - Sep 4, 2008... in endometrial cells disseminated into the peritoneal cavity may enhance their survival via local estrogen synthesis, which may lead to endometriosis. ...
Extracellularly Signal-Regulated Kinase Activity in the Human ...Journal of Clinical Endocrinology and Metabolism, MD - Sep 4, 2008Context: Endometriosis is an estrogen-dependent disease characterized by the presence of endometrial tissue outside of the uterine cavity, causing pelvic ...
Neurocrine reports positive results from Phase II endometriosis trialTrading Markets (press release), CA - Sep 4, 2008The Petal study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups - elagolix 150mg once daily, elagolix 75mg ...NBIX - OTC:CMTX
Thursday, August 28, 2008
Headlines: Possible Cause Of Endometriosis Identified
Possible Cause Of Endometriosis Identified
Science Daily (press release) - Aug 5, 20085, 2008) — Scientists at the University of Liverpool have identified an enzyme that could be responsible for a condition called endometriosis – the most ...
Secret to damage caused by endometriosis unlocked Telegraph.co.uk
Breakthrough for endometriosis sufferers as discovery offers hope ... Daily Mail
Clue to cause of womb condition
BBC News
all 24 news articles »
Science Daily (press release) - Aug 5, 20085, 2008) — Scientists at the University of Liverpool have identified an enzyme that could be responsible for a condition called endometriosis – the most ...
Secret to damage caused by endometriosis unlocked Telegraph.co.uk
Breakthrough for endometriosis sufferers as discovery offers hope ... Daily Mail
Clue to cause of womb condition
BBC News
all 24 news articles »
Sunday, June 22, 2008
Latest Endo News
Aromatase Inhibitors May Relieve Endometriosis-Associated Pain: ReviewMedscape (subscription) - Jun 20, 2008Symptoms include pelvic pain, dyspareunia, and painful bowel movements from cyclical bleeding and inflammation, which result in the formation of adhesions ...
Massage offers physical and mental benefits
Statesman Journal, OR - Jun 19, 2008... reduce scar tissue formation, improves circulation by increasing blood and nutrient flow to tissues, and reduce post surgery adhesions and swelling. ...
NeoMend Receives FDA Panel's Recommendation for Approval of ProGEL ...Earthtimes (press release), UK - Jun 17, 2008... is also developing a similar product, ProGEL-AB, for sealing surgical wound sites while also helping prevent the formation of post-surgical adhesions. ... Similar Outcomes for Patients After Laparoscopic and Open ...Abkhazia, CA - Jun 16, 2008... of incisional hernia, the number of reoperations for incisional hernia, or the number of reoperations for intraperitoneal adhesions, the authors report. ...
Haemacure Raises $7.8 Million and is Fully Funded Beyond First ...PharmaLive.com (press release), PA - Jun 16, 2008Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medicine, drug delivery and combinations with ...TSE:HAE Haemacure Raises $7.8 Million and is Fully Funded Beyond First ...istockAnalyst.com, OR - Jun 16, 2008Follow-on development will focus on surgical hemostats, wound healing,adhesion prevention, regenerative medicine, drug delivery and combinationswith ...TSE:HAE
Massage offers physical and mental benefits
Statesman Journal, OR - Jun 19, 2008... reduce scar tissue formation, improves circulation by increasing blood and nutrient flow to tissues, and reduce post surgery adhesions and swelling. ...
NeoMend Receives FDA Panel's Recommendation for Approval of ProGEL ...Earthtimes (press release), UK - Jun 17, 2008... is also developing a similar product, ProGEL-AB, for sealing surgical wound sites while also helping prevent the formation of post-surgical adhesions. ... Similar Outcomes for Patients After Laparoscopic and Open ...Abkhazia, CA - Jun 16, 2008... of incisional hernia, the number of reoperations for incisional hernia, or the number of reoperations for intraperitoneal adhesions, the authors report. ...
Haemacure Raises $7.8 Million and is Fully Funded Beyond First ...PharmaLive.com (press release), PA - Jun 16, 2008Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medicine, drug delivery and combinations with ...TSE:HAE Haemacure Raises $7.8 Million and is Fully Funded Beyond First ...istockAnalyst.com, OR - Jun 16, 2008Follow-on development will focus on surgical hemostats, wound healing,adhesion prevention, regenerative medicine, drug delivery and combinationswith ...TSE:HAE
Mom's the childish, egocentric oneSunHerald.com, MS - 9 hours agoI am a 6-foot-tall woman, and as a result of endometriosis, I have facial hair and a muscular build, too. After finding the right makeup, ...
Nitro dioxin report flawedCharleston Gazette, USA - 10 hours agoDioxin has been linked to cancer, birth defects, learning disabilities, endometriosis, infertility and suppressed immune functions. ...
Aromatase Inhibitors May Relieve Endometriosis-Associated Pain: ReviewMedscape (subscription) - Jun 20, 2008Describe the evidence supporting the use of aromatase inhibitors for endometriosis. Identify limitations of studies on the use of aromatase inhibitors for ...
Report On Presentations From The European Society For The Study Of ...Medical News Today (press release), UK - Jun 20, 2008Dr. Andrey Zaitcev and coworkers from Moscow presented a series of 19 women diagnosed with chronic pelvic pain from endometriosis who were subsequently ...
'Color Purple' -- or Is That Blue-and-White?Jewish Exponent, PA - Jun 19, 2008... including one which serves her as a spokeswoman in the battle against endometriosis, a gynecological problem she has dealt with in her life. ...
Nitro dioxin report flawedCharleston Gazette, USA - 10 hours agoDioxin has been linked to cancer, birth defects, learning disabilities, endometriosis, infertility and suppressed immune functions. ...
Aromatase Inhibitors May Relieve Endometriosis-Associated Pain: ReviewMedscape (subscription) - Jun 20, 2008Describe the evidence supporting the use of aromatase inhibitors for endometriosis. Identify limitations of studies on the use of aromatase inhibitors for ...
Report On Presentations From The European Society For The Study Of ...Medical News Today (press release), UK - Jun 20, 2008Dr. Andrey Zaitcev and coworkers from Moscow presented a series of 19 women diagnosed with chronic pelvic pain from endometriosis who were subsequently ...
'Color Purple' -- or Is That Blue-and-White?Jewish Exponent, PA - Jun 19, 2008... including one which serves her as a spokeswoman in the battle against endometriosis, a gynecological problem she has dealt with in her life. ...
Wednesday, May 28, 2008
Bid to treat painful disease
Bid to treat painful disease
A REPRODUCTIVE science unit in Edinburgh has teamed up with researchers from Aberdeen University to find new treatments for a painful disease that afflicts an estimated two million women in the UK each year.
The Medical Research Council Human Reproductive Sciences Unit in Edinburgh has set out to try to discover clues to the causes of endometriosis, a condition in which the cells that line the womb are found elsewhere in the body.It costs the economy at least £2.8 billion a year in lost working days and can also affect fertility.
http://edinburghnews.scotsman.com/health/Bid-to-treat-painful-disease.4121709.jp
A REPRODUCTIVE science unit in Edinburgh has teamed up with researchers from Aberdeen University to find new treatments for a painful disease that afflicts an estimated two million women in the UK each year.
The Medical Research Council Human Reproductive Sciences Unit in Edinburgh has set out to try to discover clues to the causes of endometriosis, a condition in which the cells that line the womb are found elsewhere in the body.It costs the economy at least £2.8 billion a year in lost working days and can also affect fertility.
http://edinburghnews.scotsman.com/health/Bid-to-treat-painful-disease.4121709.jp
Monday, March 10, 2008
March is Endometriosis Awareness Month
Endometriosis Research Center Celebrates Disease Awareness Throughout Month of March in Honor of Women and Girls Living with Painful Illness
Source: Endometriosis Research CenterMar 03, 2008 14:11:05
Mar 03, 2008 – Backed by formal legislation, the Endometriosis Research Center (ERC) is once again celebrating March as “Endometriosis Awareness Month” in honor of all those affected by the illness. Endometriosis is a painful reproductive and immunological disease in which tissue similar to the uterine lining (endometrium) migrates outside the uterus and implants in other areas of the body. The disorder, for which there is no absolute cure, affects over 5.5 million women and girls in the United States alone and over 70 million more worldwide. Often stigmatized as simply “painful periods,” Endometriosis is a puzzling and widely misunderstood illness. A primary cause of chronic pelvic pain, female infertility and a myriad of related symptoms, Endometriosis is a leading cause of gynecologic surgery, including more than half of the 600,000 hysterectomies performed in the U.S. annually. Symptoms include pelvic pain at any point in a woman or girl's menstrual cycle, infertility, pain with sexual activity, gastrointestinal difficulties, urinary tract difficulties, fatigue, allergies, and immune system dysfunction. The disease can also implant in extrapelvic areas such as the lungs, diaphragm and in rarer cases, even locations like the brain. Recent research has also shown an elevated risk of certain cancers and autoimmune disorders in those with Endometriosis, as well as malignant changes within the disease itself. Researchers remain unsure as to the definitive cause of Endometriosis, which can only be diagnosed through surgery like laparoscopy, and there is no definitive cure. Current studies indicate that genetics, immune system dysfunction or exposure to environmental toxicants may be contributing factors to disease development. Leading experts such as Robert B. Albee, Jr., MD, FACOG, ACGE and Ken Sinervo, MD, FRCSC, ACGE of the Center for Endometriosis Care, a specialty treatment center, believe multiple causative etiologies exist. The ERC maintains that Endometriosis is more than just simple "killer" cramps. “We continue to find that even now, Endometriosis remains misdiagnosed, misunderstood and ineffectively treated, despite being one of the most prevalent causes of pain in women and teens around the globe," said Michelle E. Marvel, ERC Founder and Executive Director. "Even in 2008, we see women and girls from all around the world continuing to suffer in silence with a disease that can be potentially devastating to every aspect of their lives," she noted. The economic impact of Endometriosis is staggering: American businesses lose billions of dollars each year in lost productivity and work time because of the disease. Endometriosis knows no racial or socioeconomic barriers, and can affect women ranging from adolescence to post-menopause. It can be so painful as to render a woman or teen unable to care for herself or her family, attend work, school, or social functions, or go about her normal routine. Despite the hallmark symptoms associated with the illness, the average delay in diagnosis remains an astounding nine years, and a patient will seek the counsel of five or more physicians before her pain is adequately addressed and diagnosed. Once diagnosed, it is not unusual for a patient to undergo repeat surgeries and embark on many different medical therapies in an attempt to treat her symptoms. Many such therapies carry significantly negative and long-lasting side effects, and none offer long-term relief. A growing number of younger women are being diagnosed each year, with studies indicating that as many as 70% of teenagers with chronic pelvic pain ultimately have Endometriosis proven by laparoscopy. Other reports show that as many as 41% of patients experienced Endometriosis pain early in life as an adolescent. The illness can be quite disruptive and cause significant dysfunction, especially at a time in life when self-esteem, school attendance and performance, and social involvement are all critical. Many adolescents with Endometriosis find themselves unable to attend or participate in classes, social functions, extracurricular activities, and sports due to significant pain and other symptoms of Endometriosis. Of even greater concern, recent studies have shown that Endometriosis may in fact have an even bigger impact on younger patients than older women: in patients under 22 years of age, the rate of disease recurrence was double that of older women (35% versus 19%). Studies have also revealed that the disease behaves differently in younger women; leading some researchers to believe it is a different form of Endometriosis altogether. “We are seeing the focus of research aimed at the infertility aspect of the disease, and treatment efforts continue to be directed towards medical therapies, rather than curative efforts for all women and girls,” said Marvel. “It is imperative that we recognize the far-reaching impact this illness continues to have on patients of all ages, not just those trying to conceive, in order to ensure that our daughters do not suffer as we have,” she said. The ERC is an established 501(c)3 non-profit organization focused on research facilitation, providing education and support, and raising awareness. The ERC strongly advocates early intervention, timely diagnosis, and efficacy of treatment for the disease. Through the ERC's efforts to raise public awareness, the organization hopes to facilitate better support of patients, increase physician understanding of the disease, and raise research funding leading to more effective treatments and ultimately, a cure. The organization has long pioneered and led efforts to increase recognition of Endometriosis among local, state and federal policymakers throughout the nation since the organization was founded in 1997. Through the ERC’s work, Congress previously passed the country's first-ever National Endometriosis Awareness Resolution, the first and only of its kind to formally recognize the disease and declare March as Endometriosis Awareness Month. The states of New York, Utah, Florida, Colorado, California, Wyoming, Pennsylvania, Michigan and others have also worked with the ERC to pass similar legislation recognizing the disease. The ERC is a completely free foundation available to anyone wishing to learn more about Endometriosis. The organization is sponsoring various educational, awareness and fundraising endeavors throughout March. For details, visit www.endocenter.org or contact the organization's Director of Fundraising, Denise Childs, at FundraisingDirector@EndoCenter.org.
# # #
The ERC is an established 501(c)3 non-profit organization focused on disease research facilitation, providing education and support, and raising awareness about Endometriosis.
# # #
Source: Endometriosis Research CenterMar 03, 2008 14:11:05
Mar 03, 2008 – Backed by formal legislation, the Endometriosis Research Center (ERC) is once again celebrating March as “Endometriosis Awareness Month” in honor of all those affected by the illness. Endometriosis is a painful reproductive and immunological disease in which tissue similar to the uterine lining (endometrium) migrates outside the uterus and implants in other areas of the body. The disorder, for which there is no absolute cure, affects over 5.5 million women and girls in the United States alone and over 70 million more worldwide. Often stigmatized as simply “painful periods,” Endometriosis is a puzzling and widely misunderstood illness. A primary cause of chronic pelvic pain, female infertility and a myriad of related symptoms, Endometriosis is a leading cause of gynecologic surgery, including more than half of the 600,000 hysterectomies performed in the U.S. annually. Symptoms include pelvic pain at any point in a woman or girl's menstrual cycle, infertility, pain with sexual activity, gastrointestinal difficulties, urinary tract difficulties, fatigue, allergies, and immune system dysfunction. The disease can also implant in extrapelvic areas such as the lungs, diaphragm and in rarer cases, even locations like the brain. Recent research has also shown an elevated risk of certain cancers and autoimmune disorders in those with Endometriosis, as well as malignant changes within the disease itself. Researchers remain unsure as to the definitive cause of Endometriosis, which can only be diagnosed through surgery like laparoscopy, and there is no definitive cure. Current studies indicate that genetics, immune system dysfunction or exposure to environmental toxicants may be contributing factors to disease development. Leading experts such as Robert B. Albee, Jr., MD, FACOG, ACGE and Ken Sinervo, MD, FRCSC, ACGE of the Center for Endometriosis Care, a specialty treatment center, believe multiple causative etiologies exist. The ERC maintains that Endometriosis is more than just simple "killer" cramps. “We continue to find that even now, Endometriosis remains misdiagnosed, misunderstood and ineffectively treated, despite being one of the most prevalent causes of pain in women and teens around the globe," said Michelle E. Marvel, ERC Founder and Executive Director. "Even in 2008, we see women and girls from all around the world continuing to suffer in silence with a disease that can be potentially devastating to every aspect of their lives," she noted. The economic impact of Endometriosis is staggering: American businesses lose billions of dollars each year in lost productivity and work time because of the disease. Endometriosis knows no racial or socioeconomic barriers, and can affect women ranging from adolescence to post-menopause. It can be so painful as to render a woman or teen unable to care for herself or her family, attend work, school, or social functions, or go about her normal routine. Despite the hallmark symptoms associated with the illness, the average delay in diagnosis remains an astounding nine years, and a patient will seek the counsel of five or more physicians before her pain is adequately addressed and diagnosed. Once diagnosed, it is not unusual for a patient to undergo repeat surgeries and embark on many different medical therapies in an attempt to treat her symptoms. Many such therapies carry significantly negative and long-lasting side effects, and none offer long-term relief. A growing number of younger women are being diagnosed each year, with studies indicating that as many as 70% of teenagers with chronic pelvic pain ultimately have Endometriosis proven by laparoscopy. Other reports show that as many as 41% of patients experienced Endometriosis pain early in life as an adolescent. The illness can be quite disruptive and cause significant dysfunction, especially at a time in life when self-esteem, school attendance and performance, and social involvement are all critical. Many adolescents with Endometriosis find themselves unable to attend or participate in classes, social functions, extracurricular activities, and sports due to significant pain and other symptoms of Endometriosis. Of even greater concern, recent studies have shown that Endometriosis may in fact have an even bigger impact on younger patients than older women: in patients under 22 years of age, the rate of disease recurrence was double that of older women (35% versus 19%). Studies have also revealed that the disease behaves differently in younger women; leading some researchers to believe it is a different form of Endometriosis altogether. “We are seeing the focus of research aimed at the infertility aspect of the disease, and treatment efforts continue to be directed towards medical therapies, rather than curative efforts for all women and girls,” said Marvel. “It is imperative that we recognize the far-reaching impact this illness continues to have on patients of all ages, not just those trying to conceive, in order to ensure that our daughters do not suffer as we have,” she said. The ERC is an established 501(c)3 non-profit organization focused on research facilitation, providing education and support, and raising awareness. The ERC strongly advocates early intervention, timely diagnosis, and efficacy of treatment for the disease. Through the ERC's efforts to raise public awareness, the organization hopes to facilitate better support of patients, increase physician understanding of the disease, and raise research funding leading to more effective treatments and ultimately, a cure. The organization has long pioneered and led efforts to increase recognition of Endometriosis among local, state and federal policymakers throughout the nation since the organization was founded in 1997. Through the ERC’s work, Congress previously passed the country's first-ever National Endometriosis Awareness Resolution, the first and only of its kind to formally recognize the disease and declare March as Endometriosis Awareness Month. The states of New York, Utah, Florida, Colorado, California, Wyoming, Pennsylvania, Michigan and others have also worked with the ERC to pass similar legislation recognizing the disease. The ERC is a completely free foundation available to anyone wishing to learn more about Endometriosis. The organization is sponsoring various educational, awareness and fundraising endeavors throughout March. For details, visit www.endocenter.org or contact the organization's Director of Fundraising, Denise Childs, at FundraisingDirector@EndoCenter.org.
# # #
The ERC is an established 501(c)3 non-profit organization focused on disease research facilitation, providing education and support, and raising awareness about Endometriosis.
# # #
Wednesday, February 27, 2008
Pelvic inflammatory disease
Pelvic inflammatory disease (or disorder) (PID) is a generic term for inflammation of the female uterus, fallopian tubes, and/or ovaries as it progresses to scar formation with adhesions to nearby tissues and organs. This may lead to tissue necrosis with/or without abscess formation. Pus can be released into the peritoneum. Two thirds of patients with laparoscopic evidence of previous PID were not aware they had had PID.[1] PID is often associated with sexually transmitted diseases, as it is a common result of such infections. PID is a vague term and can refer to viral, fungal, parasitic, though most often bacterial infections. PID should be classified by affected organs, the stage of the infection, and the organism(s) causing it. Although an STD is often the cause, other routes are possible, including lymphatic, postpartum, postabortal (either miscarriage or abortion) or intrauterine device (IUD) related, and hematogenous spread.
Epidemiology
In the United States, more than one million women are affected by PID each year, and the rate is highest with teenagers. Over 100,000 women become infertile in the US each year from PID.[2] N. gonorrhoea is isolated in only 40-60% of women with acute salpingitis.[3] C. trachomatis was estimated by current obgyn 9th ed to be the cause in about 60% of cases of salpingitis, which may lead to PID. It is unsure how much is due to a single organism and how much is due to multiple organisms; many other pathogens that are in normal vaginal flora become involved in PID. 10% of women in one study had asymptomatic Chlamydia trachomatis infection and 65% had asymptomatic infection with Neisseria gonorrhoeae.[3] It was noted in one study that 10-40% of untreated women with N. gonorrhoea develop PID and 20-40% of women infected with C. trachomitis developed PID.[1] PID is the leading cause of infertility. "A single episode of PID results in infertility in 13% of women."[1] This rate of infertility increases with each infection.
Diagnosis
There may be no actual symptoms of PID. If there are symptoms then fever, cervical motion tenderness, lower abdominal pain, new or different discharge, painful intercourse, or irregular menstrual bleeding may be noted. It is important to note that PID can occur and cause serious harm without causing any noticeable symptoms. Laparoscopic identification is helpful in diagnosing tubal disease, 65-90% positive predictive value in patients with presumed PID.[3] Regular Sexually transmitted disease (STD) testing is important for prevention. Treatment is usually started empirically because of the terrible complications. Definitive criteria include: histopathologic evidence of endometritis, thickened filled fallopian tubes, or laparoscopic findings. Gram-stain/smear becomes important in identification of rare and possibly more serious organisms.[1]
Differential diagnosis
Appendicitis, ectopic pregnancy, septic abortion, hemorrhagic or ruptured ovarian cysts or tumors, twisted ovarian cyst, degeneration of a myoma, and acute enteritis must be considered. Pelvic inflammatory disease is more likely to occur when there is a history of pelvic inflammatory disease, recent sexual contact, recent onset of menses, or an IUD in place or if the partner has a sexually transmitted disease.
Acute pelvic inflammatory disease is highly unlikely when recent intercourse has not taken place or an IUD is not being used. A sensitive serum pregnancy test should be obtained to rule out ectopic pregnancy. Culdocentesis will differentiate hemoperitoneum (ruptured ectopic pregnancy or hemorrhagic cyst) from pelvic sepsis (salpingitis, ruptured pelvic abscess, or ruptured appendix).
Pelvic and vaginal ultrasounds are helpful in the differential diagnosis of ectopic pregnancy of over six weeks. Laparoscopy is often utilized to diagnose pelvic inflammatory disease, and it is imperative if the diagnosis is not certain or if the patient has not responded to antibiotic therapy after 48 hours.
No single test has adequate sensitivity and specificity to diagnose pelvic inflammatory disease. A large mulitsite U.S. study found that cervical motion tenderness as a minimum clinical criterion increases the sensitivity of the CDC diagnostic criteria from 83% to 95%. However, even the modified 2002 CDC criteria does not identify women with subclinical disease.[4]
Prognosis
Although the PID infection itself may be cured, effects of the infection may be permanent. This makes early identification by someone who can prescribe appropriate curative treatment so important in the prevention of damage to the reproductive system. Since early gonococcal infection may be asymptomatic, regular screening of individuals at risk for common agents (history of multiple partners, history of any unprotected sex, or people with symptoms) or because of certain procedures (post pelvic operation, postpartum, miscarriage or abortion). Prevention is also very important in maintaining viable reproduction capabilities.
If the initial infection is mostly in the lower tract, after treatment the person may have few difficulties. If the infection is in the fallopian tubes or ovaries, more serious complications are more likely to occur.
Complications
PID can cause scarring inside the reproductive organs, which can later cause serious complications, including chronic pelvic pain, infertility (difficulty becoming pregnant), ectopic pregnancy (the leading cause of pregnancy-related deaths in adult females), and other dangerous complications of pregnancy. Multiple infections and infections that are treated later are more likely to result in complications.
Infertile women may wish to see a specialist, because there may be a possibility in restoring fertility after scarring. Traditionally tuboplastic surgery was the main approach to correct tubal obstruction or adhesion formation, however success rates tended to be very limited. In vitro fertilization (IVF) was developed to bypass tubal problems and has become the main treatment for patients who want to become pregnant.
Treatment
Treatment depends on the cause and generally involves use of antibiotic therapy. If the patient has not improved within two to three days after beginning treatment with the antibiotics, they should return to the hospital for further treatment. Drugs should also be given orally and/or intravaneously to the patient while in the hospital to begin treatment immediately to increase the effectiveness of antibiotic treatment. Hospitalization may be necessary if Tubo-ovarian abscess, very ill, immunodeficient, pregnancy, incompetence, or because this or something else life threatening can not be ruled out. Treating partners for STD's is a very important part of treatment and prevention. Anyone with PID and partners of patients with PID since six months prior to diagnosis should be treated to prevent reinfection. Psychotherapy is highly recommended to women diagnosed with PID as the fear of redeveloping the disease after being cured may exist. It is important for a patient to communicate any issues and/or uncertainties they may have to a doctor, especially a specialist such as a gynecologist, and in doing so, to seek follow-up care.
A systematic review of the literature related to PID treatment was performed prior to the 2006 CDC sexually transmitted diseases treatment guidelines. Strong evidence suggests that neither site nor route of antibiotic administration affects the short or long-term major outcome of women with mild or moderate disease. Data on women with severe disease was inadequate to influence the results of the study. [5]
Prevention
Risk reduction against sexually transmitted diseases through abstinence or barrier methods such as condoms, see human sexual behavior for other listings.
Going to the doctor immediately if symptoms of PID, sexually transmitted diseases appear, or after learning that a current or former sex partner has, or might have had a sexually transmitted disease.
Getting regular gynecological (pelvic) exams with STD testing to screen for symptomless PID.[6]
Discussing sexual history with a trusted physician in order to get properly screened for sexually transmitted diseases.
Regularly scheduling STD testing with a physician and discussing which tests will be performed that session.
Getting a STD history from your current partner and insisting they be tested and treated before intercourse.
Understanding when a partner says that they have been STD tested they usually mean chlamydia and gonorrhea in the US, but that those are not all of the sexually transmissible diseases.
Treating partners to prevent reinfection or spreading the infection to other people.
Other diseases that can lead to or be involved in PID
Salpingitis, any infection of the fallopian tubes.
Tubo-ovarian abscess an abscess of the fallopian tube or ovary.
Endometritis
Pelvic peritonitis
The Dalkon Shield (withdrawn from the market in 1975 for this reason)
Bacterial Vaginosis
References
^ a b c d Loscalzo, Joseph; Andreoli, Thomas E.; Cecil, Russell L.; Carpenter, Charles A.; Griggs, Robert C. (2001). Cecil essentials of medicine. Philadelphia: W.B. Saunders. ISBN 0-7216-8179-4.
^ STD Facts - Pelvic inflammatory disease (PID). Retrieved on 2007-11-23.
^ a b c Lauren Nathan; DeCherney, Alan H.; Pernoll, Martin L. (2003). Current obstetric & gynecologic diagnosis & treatment. New York: Lange Medical Books/McGraw-Hill. ISBN 0-8385-1401-4.
^ Blenning CE, Muench J, Judkins DZ, Roberts KT (2007). "Clinical inquiries. Which tests are most useful for diagnosing PID?". J Fam Pract 56 (3): 216–20. PMID 17343812.
^ Walker CK, Wiesenfeld HC (2007). "Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines". Clin. Infect. Dis. 44 Suppl 3: S111–22. doi:10.1086/511424. PMID 17342664.
^ Smith KJ, Cook RL, Roberts MS (2007). "Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: influence on the cost-effectiveness of different screening intervals". Value Health 10 (5): 358–66. doi:10.1111/j.1524-4733.2007.00189.x. PMID 17888100.
External links
NIH/Medline
CDC
Pelvic Inflammatory Disease (PID; Salpingitis, Endometritis)
Epidemiology
In the United States, more than one million women are affected by PID each year, and the rate is highest with teenagers. Over 100,000 women become infertile in the US each year from PID.[2] N. gonorrhoea is isolated in only 40-60% of women with acute salpingitis.[3] C. trachomatis was estimated by current obgyn 9th ed to be the cause in about 60% of cases of salpingitis, which may lead to PID. It is unsure how much is due to a single organism and how much is due to multiple organisms; many other pathogens that are in normal vaginal flora become involved in PID. 10% of women in one study had asymptomatic Chlamydia trachomatis infection and 65% had asymptomatic infection with Neisseria gonorrhoeae.[3] It was noted in one study that 10-40% of untreated women with N. gonorrhoea develop PID and 20-40% of women infected with C. trachomitis developed PID.[1] PID is the leading cause of infertility. "A single episode of PID results in infertility in 13% of women."[1] This rate of infertility increases with each infection.
Diagnosis
There may be no actual symptoms of PID. If there are symptoms then fever, cervical motion tenderness, lower abdominal pain, new or different discharge, painful intercourse, or irregular menstrual bleeding may be noted. It is important to note that PID can occur and cause serious harm without causing any noticeable symptoms. Laparoscopic identification is helpful in diagnosing tubal disease, 65-90% positive predictive value in patients with presumed PID.[3] Regular Sexually transmitted disease (STD) testing is important for prevention. Treatment is usually started empirically because of the terrible complications. Definitive criteria include: histopathologic evidence of endometritis, thickened filled fallopian tubes, or laparoscopic findings. Gram-stain/smear becomes important in identification of rare and possibly more serious organisms.[1]
Differential diagnosis
Appendicitis, ectopic pregnancy, septic abortion, hemorrhagic or ruptured ovarian cysts or tumors, twisted ovarian cyst, degeneration of a myoma, and acute enteritis must be considered. Pelvic inflammatory disease is more likely to occur when there is a history of pelvic inflammatory disease, recent sexual contact, recent onset of menses, or an IUD in place or if the partner has a sexually transmitted disease.
Acute pelvic inflammatory disease is highly unlikely when recent intercourse has not taken place or an IUD is not being used. A sensitive serum pregnancy test should be obtained to rule out ectopic pregnancy. Culdocentesis will differentiate hemoperitoneum (ruptured ectopic pregnancy or hemorrhagic cyst) from pelvic sepsis (salpingitis, ruptured pelvic abscess, or ruptured appendix).
Pelvic and vaginal ultrasounds are helpful in the differential diagnosis of ectopic pregnancy of over six weeks. Laparoscopy is often utilized to diagnose pelvic inflammatory disease, and it is imperative if the diagnosis is not certain or if the patient has not responded to antibiotic therapy after 48 hours.
No single test has adequate sensitivity and specificity to diagnose pelvic inflammatory disease. A large mulitsite U.S. study found that cervical motion tenderness as a minimum clinical criterion increases the sensitivity of the CDC diagnostic criteria from 83% to 95%. However, even the modified 2002 CDC criteria does not identify women with subclinical disease.[4]
Prognosis
Although the PID infection itself may be cured, effects of the infection may be permanent. This makes early identification by someone who can prescribe appropriate curative treatment so important in the prevention of damage to the reproductive system. Since early gonococcal infection may be asymptomatic, regular screening of individuals at risk for common agents (history of multiple partners, history of any unprotected sex, or people with symptoms) or because of certain procedures (post pelvic operation, postpartum, miscarriage or abortion). Prevention is also very important in maintaining viable reproduction capabilities.
If the initial infection is mostly in the lower tract, after treatment the person may have few difficulties. If the infection is in the fallopian tubes or ovaries, more serious complications are more likely to occur.
Complications
PID can cause scarring inside the reproductive organs, which can later cause serious complications, including chronic pelvic pain, infertility (difficulty becoming pregnant), ectopic pregnancy (the leading cause of pregnancy-related deaths in adult females), and other dangerous complications of pregnancy. Multiple infections and infections that are treated later are more likely to result in complications.
Infertile women may wish to see a specialist, because there may be a possibility in restoring fertility after scarring. Traditionally tuboplastic surgery was the main approach to correct tubal obstruction or adhesion formation, however success rates tended to be very limited. In vitro fertilization (IVF) was developed to bypass tubal problems and has become the main treatment for patients who want to become pregnant.
Treatment
Treatment depends on the cause and generally involves use of antibiotic therapy. If the patient has not improved within two to three days after beginning treatment with the antibiotics, they should return to the hospital for further treatment. Drugs should also be given orally and/or intravaneously to the patient while in the hospital to begin treatment immediately to increase the effectiveness of antibiotic treatment. Hospitalization may be necessary if Tubo-ovarian abscess, very ill, immunodeficient, pregnancy, incompetence, or because this or something else life threatening can not be ruled out. Treating partners for STD's is a very important part of treatment and prevention. Anyone with PID and partners of patients with PID since six months prior to diagnosis should be treated to prevent reinfection. Psychotherapy is highly recommended to women diagnosed with PID as the fear of redeveloping the disease after being cured may exist. It is important for a patient to communicate any issues and/or uncertainties they may have to a doctor, especially a specialist such as a gynecologist, and in doing so, to seek follow-up care.
A systematic review of the literature related to PID treatment was performed prior to the 2006 CDC sexually transmitted diseases treatment guidelines. Strong evidence suggests that neither site nor route of antibiotic administration affects the short or long-term major outcome of women with mild or moderate disease. Data on women with severe disease was inadequate to influence the results of the study. [5]
Prevention
Risk reduction against sexually transmitted diseases through abstinence or barrier methods such as condoms, see human sexual behavior for other listings.
Going to the doctor immediately if symptoms of PID, sexually transmitted diseases appear, or after learning that a current or former sex partner has, or might have had a sexually transmitted disease.
Getting regular gynecological (pelvic) exams with STD testing to screen for symptomless PID.[6]
Discussing sexual history with a trusted physician in order to get properly screened for sexually transmitted diseases.
Regularly scheduling STD testing with a physician and discussing which tests will be performed that session.
Getting a STD history from your current partner and insisting they be tested and treated before intercourse.
Understanding when a partner says that they have been STD tested they usually mean chlamydia and gonorrhea in the US, but that those are not all of the sexually transmissible diseases.
Treating partners to prevent reinfection or spreading the infection to other people.
Other diseases that can lead to or be involved in PID
Salpingitis, any infection of the fallopian tubes.
Tubo-ovarian abscess an abscess of the fallopian tube or ovary.
Endometritis
Pelvic peritonitis
The Dalkon Shield (withdrawn from the market in 1975 for this reason)
Bacterial Vaginosis
References
^ a b c d Loscalzo, Joseph; Andreoli, Thomas E.; Cecil, Russell L.; Carpenter, Charles A.; Griggs, Robert C. (2001). Cecil essentials of medicine. Philadelphia: W.B. Saunders. ISBN 0-7216-8179-4.
^ STD Facts - Pelvic inflammatory disease (PID). Retrieved on 2007-11-23.
^ a b c Lauren Nathan; DeCherney, Alan H.; Pernoll, Martin L. (2003). Current obstetric & gynecologic diagnosis & treatment. New York: Lange Medical Books/McGraw-Hill. ISBN 0-8385-1401-4.
^ Blenning CE, Muench J, Judkins DZ, Roberts KT (2007). "Clinical inquiries. Which tests are most useful for diagnosing PID?". J Fam Pract 56 (3): 216–20. PMID 17343812.
^ Walker CK, Wiesenfeld HC (2007). "Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines". Clin. Infect. Dis. 44 Suppl 3: S111–22. doi:10.1086/511424. PMID 17342664.
^ Smith KJ, Cook RL, Roberts MS (2007). "Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: influence on the cost-effectiveness of different screening intervals". Value Health 10 (5): 358–66. doi:10.1111/j.1524-4733.2007.00189.x. PMID 17888100.
External links
NIH/Medline
CDC
Pelvic Inflammatory Disease (PID; Salpingitis, Endometritis)
Tuesday, February 26, 2008
How to look good
Kudo's from EndoTimes!
23.02.2008
MIRANDA Bond believes her organic make-up company, which has been operating for just over a year, will soon be the biggest of its kind in the world.
These are not modest aims but she's confident she's on track. After all, she says the company is doubling its sales every three months and is adding one or two people a month to the staff. The growth has been phenomenal, something most companies can only dream of. But contrary to popular wisdom, Ms Bond and her partner Jenni Williams are now pulling the reins in on their growth, slowing things down so they're only taking baby steps. It's a strategy they believe will eventually make their company formidable. Inika, headquartered in Thirroul south of Sydney, makes cosmetics, but it stands out from mainstream cosmetic companies by making them out of Australian minerals, 100 per cent certified vegan and 100 per cent organic. The products were born out of the website Ms Bond established with Ms Williams, called www.thrivinghealthywomen.com.au. The women had come together because of health issues both had experienced. Ms Bond had been diagnosed with endometriosis and was told she couldn't have any children. When she was also told hormone levels can affect fertility and that chemicals in some cosmetics can affect a body's hormone balance, she got some progesterone cream, threw out all her cosmetics and changed her diet. Three months later she was pregnant. Ms William's son is allergic to dairy, nuts, fish, eggs and is chronically sensitive to chemicals, so much so that if she touched his skin while she was wearing certain cosmetics he would have a drastic reaction. As both women embarked on their toxic-free lifestyle, they set up the website as a database of articles that related to women's health. Soon they were fielding emails from women around the world looking for organic make-up, many because they had sensitive skins or allergies. After doing some research into organic make-up suppliers, they decided to have a go at making it themselves. "Within two weeks we'd found the best natural formulators in Australia,'' Ms Ward said. Inika, which means "small earth'' in Hindi, was formed in March 2006 and by the middle of the year they had products in shops. As factories in Western Australia and South Australia churned out their foundations, lipsticks, mascaras and eye-shadows, the pace at which the company moved was extraordinary. Their big break, Ms Ward said, was exhibiting at the 2006 Organic Expo in Sydney. "We signed up so many accounts with shops and salons. And within three to four months we were in 21 David Jones stores around the country. "We had no strategy really. Everything just fell into place. The strategy came later.'' Part of that was to make the move overseas, a bold step considering the products weren't very established in Australia. The main reason, Ms Bond said, was that the population in Australia wasn't big enough for their company to be sustainable. And the need for a wider market was because of perceptions, Ms Bond said. "A lot of people think that because a product is 'natural' it's not as good, but our products are up there with the global make-up houses,'' she said. With the help of Austrade, the products are now being sold in New Zealand, Slovenia, Thailand, the UK and Canada, and are considered good enough to take on more established global natural cosmetics companies such as Jane Iredale and Dr Hauschka. It's in the UK that Inika is achieving great success, so much so the company has opened offices in London and a UK website. And this is where their new growth strategy comes in. Europe promises to be a huge market, but at the moment the products are sold only in Slovenia. Likewise Asia, but at the moment they're sold only in Thailand. North America will also be lucrative, but they're sold at the moment only in Canada. "The product is sought after in China and Japan, but Austrade said don't do it, you'll implode,'' Ms Bond said. Likewise with North America. The company is leaving the US push until last. "Now that we've got a team in the UK, it's easier to manage growth,'' she said. "Now we can continue to build in the UK and Europe. "Our strategy is to keep a handle on things, to not lose control.'' And one of the challenges of growth is maintaining the company's independence. "We'd like to keep the autonomy we have now, and keep the intimacy,'' Ms Bond said.
Go to www.inika.com.au
23.02.2008
MIRANDA Bond believes her organic make-up company, which has been operating for just over a year, will soon be the biggest of its kind in the world.
These are not modest aims but she's confident she's on track. After all, she says the company is doubling its sales every three months and is adding one or two people a month to the staff. The growth has been phenomenal, something most companies can only dream of. But contrary to popular wisdom, Ms Bond and her partner Jenni Williams are now pulling the reins in on their growth, slowing things down so they're only taking baby steps. It's a strategy they believe will eventually make their company formidable. Inika, headquartered in Thirroul south of Sydney, makes cosmetics, but it stands out from mainstream cosmetic companies by making them out of Australian minerals, 100 per cent certified vegan and 100 per cent organic. The products were born out of the website Ms Bond established with Ms Williams, called www.thrivinghealthywomen.com.au. The women had come together because of health issues both had experienced. Ms Bond had been diagnosed with endometriosis and was told she couldn't have any children. When she was also told hormone levels can affect fertility and that chemicals in some cosmetics can affect a body's hormone balance, she got some progesterone cream, threw out all her cosmetics and changed her diet. Three months later she was pregnant. Ms William's son is allergic to dairy, nuts, fish, eggs and is chronically sensitive to chemicals, so much so that if she touched his skin while she was wearing certain cosmetics he would have a drastic reaction. As both women embarked on their toxic-free lifestyle, they set up the website as a database of articles that related to women's health. Soon they were fielding emails from women around the world looking for organic make-up, many because they had sensitive skins or allergies. After doing some research into organic make-up suppliers, they decided to have a go at making it themselves. "Within two weeks we'd found the best natural formulators in Australia,'' Ms Ward said. Inika, which means "small earth'' in Hindi, was formed in March 2006 and by the middle of the year they had products in shops. As factories in Western Australia and South Australia churned out their foundations, lipsticks, mascaras and eye-shadows, the pace at which the company moved was extraordinary. Their big break, Ms Ward said, was exhibiting at the 2006 Organic Expo in Sydney. "We signed up so many accounts with shops and salons. And within three to four months we were in 21 David Jones stores around the country. "We had no strategy really. Everything just fell into place. The strategy came later.'' Part of that was to make the move overseas, a bold step considering the products weren't very established in Australia. The main reason, Ms Bond said, was that the population in Australia wasn't big enough for their company to be sustainable. And the need for a wider market was because of perceptions, Ms Bond said. "A lot of people think that because a product is 'natural' it's not as good, but our products are up there with the global make-up houses,'' she said. With the help of Austrade, the products are now being sold in New Zealand, Slovenia, Thailand, the UK and Canada, and are considered good enough to take on more established global natural cosmetics companies such as Jane Iredale and Dr Hauschka. It's in the UK that Inika is achieving great success, so much so the company has opened offices in London and a UK website. And this is where their new growth strategy comes in. Europe promises to be a huge market, but at the moment the products are sold only in Slovenia. Likewise Asia, but at the moment they're sold only in Thailand. North America will also be lucrative, but they're sold at the moment only in Canada. "The product is sought after in China and Japan, but Austrade said don't do it, you'll implode,'' Ms Bond said. Likewise with North America. The company is leaving the US push until last. "Now that we've got a team in the UK, it's easier to manage growth,'' she said. "Now we can continue to build in the UK and Europe. "Our strategy is to keep a handle on things, to not lose control.'' And one of the challenges of growth is maintaining the company's independence. "We'd like to keep the autonomy we have now, and keep the intimacy,'' Ms Bond said.
Go to www.inika.com.au
Monday, February 25, 2008
Many inflammatory bowel disease mimic gynecological disorders in its clinical presentation
Endometriosis is a condition of unknown etiology in which endometrial tissue occurs at extra-uterine sites, including ovaries, fallopian tubes, and gastrointestinal tract. It usually occurs between 30 and 40 years of age. Four to 17% of menstruating women develop endometriosis. When the disease involves the small bowel, it usually has a benign course, but in rare circumstances, it may present as abdominal emergency. Invasive bowel endometriosis can present as bowel obstruction. The major cause of obstruction is stricture formation and adhesions, which occasionally mimic Crohn's disease or a malignancy in its clinical presentation.
Gastrointestinal endometriosis is suggested by dysmenorrhea, menorrhagia or perimenstrual symptoms. Frank intestinal symptoms are usually associated with intestinal obstruction. While intestinal symptoms may occur during or be exacerbated by the menses, this association may not always be present. The symptoms coincide with menstruation in only 18-40% of the cases. A recurring crampy lower or mid-abdominal pain is the most common presenting symptom for both intestinal endometriosis and Crohn's disease. Other symptoms which may occur in both entities include diarrhea, constipation, nausea, vomiting, fever, anorexia, and weight loss.
A case report published on January 7, 2008 in the World Journal of Gastroenterology describes a desperate patient who presented to Dr. Zafer Teke of Pamukkale University Hospital, Turkey, in 2006. This patient was quite a challenge for Dr. Teke. She was 31 years old with perimenstrual lower and mid-abdominal pain irradiating to the back, and lower abdominal fullness for 3 years, at first monthly, but later continuous, and gradually increasing in severity. She gave a history of moderate dysmenorrhea and menorrhagia, but no dyspareunia. Her only medication was an oral contraceptive. She had delivered a healthy baby.
Her gynecologist at a women's health clinic had diagnosed her with small bowel endometriosis, based on interviews and her clinical course. As only oral contraceptive therapy was started, the symptoms due to partial mechanical bowel obstruction had gradually improved. The lack of response to oral contraceptive therapy had encouraged her gynecologist to perform an exploratory laparotomy. The gynecologist was only able to perform a biopsy from the highly inflamed areas. Biopsy results were non-specific inflammation. The patient was then referred to Dr. Teke's institution to identify the underlying pathology.
In an effort to improve the condition of the patient, Dr. Teke initially decided to treat the patient with conservative measures, and the patient responded to this treatment. However, after ingesting a small amount of food she again complained of abdominal pain, and plain abdominal radiography once more showed mechanical bowel obstruction. After improvement with conservative management and obtaining adequate informed consent, the patient was operated on by Dr. Teke. The operative appearance was thought to indicate Crohn's disease, but in view of the close relationship of the ovaries, tubes and uterus, an immediate gynecological opinion was obtained. The on-call gynecology registrar did not consider the appearance to be due to primary gynecological pathology. An approximately 40 cm segment of distal small bowel had four strictures and three internal fistulas. Histopathological examination of the resected specimen was consistent with Crohn's disease. The surgical treatment led to rapid resolution of the symptoms.
The differential diagnosis of Crohn's disease with intestinal endometriosis may be difficult pre-operatively. Dr. Teke noted that even lower gastrointestinal flexible endoscopy may show no findings suggestive of Crohn's disease, as in his patient. Indeed, there may be a similarity between the two entities in terms of clinical presentation, symptomatology, radiological appearances, surgical and pathological findings. Due to a relatively high percentage of endometriosis among the female population of child-bearing age globally, and the unavailability of a precise test differentiating Crohn's disease from bowel endometriosis, this case reported by Dr. Teke is surely worth the attention of both doctors and women at large.
###
Reference: Teke Z, Aytekin FO, Atalay AO, Demirkan NC. Crohn's Disease Complicated by Multiple Stenoses and Internal Fistulas Clinically Mimicking Small Bowel Endometriosis. World J Gastroenterol 2008, January 7; 14(1): 146-151 http://www.wjgnet.com/1007-9327/14/146.asp
Correspondence to: Zafer Teke, MD, Department of General Surgery, Pamukkale University, School of Medicine, Kuspinar Mah. Emek Cad. Oyku Sitesi, A-Blok, No:121, K:4, D:10, 20020, Denizli, Turkey. zteke_md@yahoo.com Telephone: +90-542-2644046 Fax: +90-258-2134922
Gastrointestinal endometriosis is suggested by dysmenorrhea, menorrhagia or perimenstrual symptoms. Frank intestinal symptoms are usually associated with intestinal obstruction. While intestinal symptoms may occur during or be exacerbated by the menses, this association may not always be present. The symptoms coincide with menstruation in only 18-40% of the cases. A recurring crampy lower or mid-abdominal pain is the most common presenting symptom for both intestinal endometriosis and Crohn's disease. Other symptoms which may occur in both entities include diarrhea, constipation, nausea, vomiting, fever, anorexia, and weight loss.
A case report published on January 7, 2008 in the World Journal of Gastroenterology describes a desperate patient who presented to Dr. Zafer Teke of Pamukkale University Hospital, Turkey, in 2006. This patient was quite a challenge for Dr. Teke. She was 31 years old with perimenstrual lower and mid-abdominal pain irradiating to the back, and lower abdominal fullness for 3 years, at first monthly, but later continuous, and gradually increasing in severity. She gave a history of moderate dysmenorrhea and menorrhagia, but no dyspareunia. Her only medication was an oral contraceptive. She had delivered a healthy baby.
Her gynecologist at a women's health clinic had diagnosed her with small bowel endometriosis, based on interviews and her clinical course. As only oral contraceptive therapy was started, the symptoms due to partial mechanical bowel obstruction had gradually improved. The lack of response to oral contraceptive therapy had encouraged her gynecologist to perform an exploratory laparotomy. The gynecologist was only able to perform a biopsy from the highly inflamed areas. Biopsy results were non-specific inflammation. The patient was then referred to Dr. Teke's institution to identify the underlying pathology.
In an effort to improve the condition of the patient, Dr. Teke initially decided to treat the patient with conservative measures, and the patient responded to this treatment. However, after ingesting a small amount of food she again complained of abdominal pain, and plain abdominal radiography once more showed mechanical bowel obstruction. After improvement with conservative management and obtaining adequate informed consent, the patient was operated on by Dr. Teke. The operative appearance was thought to indicate Crohn's disease, but in view of the close relationship of the ovaries, tubes and uterus, an immediate gynecological opinion was obtained. The on-call gynecology registrar did not consider the appearance to be due to primary gynecological pathology. An approximately 40 cm segment of distal small bowel had four strictures and three internal fistulas. Histopathological examination of the resected specimen was consistent with Crohn's disease. The surgical treatment led to rapid resolution of the symptoms.
The differential diagnosis of Crohn's disease with intestinal endometriosis may be difficult pre-operatively. Dr. Teke noted that even lower gastrointestinal flexible endoscopy may show no findings suggestive of Crohn's disease, as in his patient. Indeed, there may be a similarity between the two entities in terms of clinical presentation, symptomatology, radiological appearances, surgical and pathological findings. Due to a relatively high percentage of endometriosis among the female population of child-bearing age globally, and the unavailability of a precise test differentiating Crohn's disease from bowel endometriosis, this case reported by Dr. Teke is surely worth the attention of both doctors and women at large.
###
Reference: Teke Z, Aytekin FO, Atalay AO, Demirkan NC. Crohn's Disease Complicated by Multiple Stenoses and Internal Fistulas Clinically Mimicking Small Bowel Endometriosis. World J Gastroenterol 2008, January 7; 14(1): 146-151 http://www.wjgnet.com/1007-9327/14/146.asp
Correspondence to: Zafer Teke, MD, Department of General Surgery, Pamukkale University, School of Medicine, Kuspinar Mah. Emek Cad. Oyku Sitesi, A-Blok, No:121, K:4, D:10, 20020, Denizli, Turkey. zteke_md@yahoo.com Telephone: +90-542-2644046 Fax: +90-258-2134922
Tuesday, February 12, 2008
Stephanie St. James raises awareness for Endometriosis
About This Video
Stephanie St. James raises awareness for Endome... (more)
Added: September 28, 2007
Stephanie St. James raises awareness for Endometriosis on NBC's iVillage Live
Added: September 28, 2007
Category: People & Blogs
Tags:
Stephanie St. James Endometriosis oprah the color purple jeanette bayardelle michelle williams fantasia
...And Oprah is her boss!
Thx Glynis
Thursday, January 31, 2008
Treatment strategies for endometriosis.
Rodgers AK, Falcone T.
Department of Obstetrics and Gynecology, The Cleveland Clinic, Department of Obstetrics and Gynecology-A81, 9500 Euclid Avenue, Cleveland, Ohio 44159, USA.
BACKGROUND: Endometriosis is a common chronic disease that causes symptoms of pain and infertility. The pain syndrome can be quite incapacitating. The pain symptoms usually originate in the reproductive organs but can also involve the urinary or intestinal tracts if endometriosis implantation has occurred there. The presentation and physical appearance of endometriosis is extremely variable and can be characterized by a chronic intraperitoneal inflammatory process and adhesions. The only definitive diagnostic technique is laparoscopy. OBJECTIVE: To review current literature on the treatment strategies for endometriosis. METHODS: Review of Pubmed, Cochrane database and Medline for current review articles and studies regarding the current treatment strategies for endometriosis. RESULTS: Initial treatment is surgical or medical. Medical therapy is often used as a first-line therapy and can also be used in conjunction with those patients who undergo surgical therapy for pain. No medical therapy has proven effective for infertility. Medical therapy consists mostly of hormonal suppressive therapy in which the medication causes a downregulation of the hypothalamus-pituitary-ovarian pathway. Non-steroidal anti-inflammatory drugs and oral contraceptives are often used as an initial approach even without a definitive diagnosis. Progestins, such as oral norethindrone and depot medroxyprogesterone, are effective while using them but have a high recurrence rate. The norgestrol intrauterine device is also quite effective at relieving pain associated with endometriosis, especially pain arising during menses as well as from lesions in the rectovaginal tissue. Gonadotropin-releasing hormone agonists induce a pseudomenopausal state and have significant side effects, such as hot flashes and genital atrophy. 'Add-back' therapy with a progestin has been shown to relieve most of these drug related symptoms. Gonadotropin-releasing hormone agonists are also very effective at relieving symptoms of pain during treatment but are also associated with a high recurrence rate. New drug therapies that are under investigation are aromatase inhibitors and immunomodulators. Furthermore, new delivery systems are being investigated that may also improve the patient response.
PMID: 18201147 [PubMed - in process]
Department of Obstetrics and Gynecology, The Cleveland Clinic, Department of Obstetrics and Gynecology-A81, 9500 Euclid Avenue, Cleveland, Ohio 44159, USA.
BACKGROUND: Endometriosis is a common chronic disease that causes symptoms of pain and infertility. The pain syndrome can be quite incapacitating. The pain symptoms usually originate in the reproductive organs but can also involve the urinary or intestinal tracts if endometriosis implantation has occurred there. The presentation and physical appearance of endometriosis is extremely variable and can be characterized by a chronic intraperitoneal inflammatory process and adhesions. The only definitive diagnostic technique is laparoscopy. OBJECTIVE: To review current literature on the treatment strategies for endometriosis. METHODS: Review of Pubmed, Cochrane database and Medline for current review articles and studies regarding the current treatment strategies for endometriosis. RESULTS: Initial treatment is surgical or medical. Medical therapy is often used as a first-line therapy and can also be used in conjunction with those patients who undergo surgical therapy for pain. No medical therapy has proven effective for infertility. Medical therapy consists mostly of hormonal suppressive therapy in which the medication causes a downregulation of the hypothalamus-pituitary-ovarian pathway. Non-steroidal anti-inflammatory drugs and oral contraceptives are often used as an initial approach even without a definitive diagnosis. Progestins, such as oral norethindrone and depot medroxyprogesterone, are effective while using them but have a high recurrence rate. The norgestrol intrauterine device is also quite effective at relieving pain associated with endometriosis, especially pain arising during menses as well as from lesions in the rectovaginal tissue. Gonadotropin-releasing hormone agonists induce a pseudomenopausal state and have significant side effects, such as hot flashes and genital atrophy. 'Add-back' therapy with a progestin has been shown to relieve most of these drug related symptoms. Gonadotropin-releasing hormone agonists are also very effective at relieving symptoms of pain during treatment but are also associated with a high recurrence rate. New drug therapies that are under investigation are aromatase inhibitors and immunomodulators. Furthermore, new delivery systems are being investigated that may also improve the patient response.
PMID: 18201147 [PubMed - in process]
Subscribe to:
Posts (Atom)